Shares are now ‘ex-dividend' for Optibiotix's 'ProBiotix Health' business, which will be spun off onto the AQSE Growth Market - with an associated fundraise - at the end of this month. Additionally, SkinBioTherapeutics (SBTX), in which it has a 20.73% stake, has just announced half-year results - that the market did not like. So, how does the valuation stack up now?
Cenkos is house broker to Optibiotix (OPTI) so it is biased. I own shed loads of shares so am biased. The forecasts in the note out today include sod all for the three major deals announced at Christmas. So they will be increased. Read into this what you want. My pension will be buying more shares at around the current level if it can.
OptiBiotix Health (OPTI) has announced that it intends to seek admission of its ProBiotix Health business onto the AQSE Growth Market with an associated fund raise of approximately £2.5 million at an indicative premoney valuation of £22.5 million and a distribution in specie. With, at a 35.5p share price, OptiBiotix as a whole currently capitalised at £31.3 million, is this good news? You bet!
OptiBiotix Health (OPTI) has issued a trading update commenting that 2021 “total invoiced sales for the group were £2.2m (2020: £1.5m) an increase of 46.7% on the previous year and in line with market expectations” and including that it “has made good progress against its stated aims of focusing on a smaller number of large partners in key strategic markets and expects to see the benefits of these in 2022 and beyond”. What does that mean at the bottom-line?
OptiBiotix Health (OPTI) has made what it describes as a “Commercial and strategy update”, including arguing “look forward with confidence to further commercial progress of the group in the current year and beyond”. What does that though mean tangibly?
